AR and metastatic neoplasm: Since the androgen receptor (AR) plays a pivotal role in the development and progression of PCa, androgen‐deprivation therapy (ADT) targeting AR signalling has become the mainstay systemic treatment for patients with locally advanced, biochemically recurrent and metastatic disease.2